Influence of inflammatory cytokines on arteriogenesis

Microcirculation

Volumn 10, Issue 3-4, 2003, Pages 371-379

  Buschmann, Ivo ^a   Heil, Matthias ^b   Jost, Marco ^a   Schaper, Wolfgang ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

Arteriogenesis; Chemokines; Cytokines; Monocytes

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ACIDIC FIBROBLAST GROWTH FACTOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; BEVACIZUMAB; COLONY STIMULATING FACTOR 1; CYTOKINE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GELATINASE A; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; AUTACOID;

ANGIOGENESIS; APOPTOSIS; ARTERIOLE; ARTERY OCCLUSION; ARTICLE; ASCITES TUMOR; BLOOD FLOW VELOCITY; BLOOD PRESSURE; BLOOD VESSEL WALL; CAPILLARY; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CLINICAL STUDY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIUM CELL; FEASIBILITY STUDY; HEMATOLOGIC DISEASE; HEMODYNAMICS; HUMAN; HYPOXIA; ISCHEMIA; MALIGNANT NEOPLASTIC DISEASE; MICROCIRCULATION; MONOCYTE; MUSCLE INJURY; MUSCLE ISCHEMIA; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; PUBLICATION; RISK REDUCTION; SMOOTH MUSCLE FIBER; SOLID TUMOR; TREATMENT PLANNING; TUMOR GROWTH; ANIMAL; ARTERY; COLLATERAL CIRCULATION; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PHYSIOLOGY; REVIEW;

ANIMALS; ARTERIES; COLLATERAL CIRCULATION; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; MICROCIRCULATION; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 0242336630     PISSN: 10739688     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mn.7800199     Document Type: Article

References (77)

1. Arras M, Ito WD, Scholz D, Winkler B, Schaper J, Schaper W. (1998). Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest 101:40-50.
2. Bae MK, Ahn MY, Jeong JW, Bae MH, Lee YM, Bae SK, Park JW, Kim KR, Kim KW. (2002). Jab1 interacts directly with HIF-1alpha and regulates its stability. J Biol Chem 277:9-12.
3. Bauters C, Six I, Meurice T, Van Belle E. (1999). Growth factors and endothelial dysfunction. Drugs 59:11-15.
4. Bouloumie A, Drexler HC, Lafontan M, Busse R. (1998). Leptin, the product of Ob gene, promotes angiogenesis. Circ Res 83:1059-1066.
5. Bouloumie A, Marumo T, Lafontan M, Busse R. (1999). Leptin induces oxidative stress in human endothelial cells. FASEB J 13:1231-1238.
6. Buschmann IR, Hoefer IE, van Royen N, Katzer E, Braun-Dulleaus R, Heil M, Kosfin S, Bode C, Schaper W. (2001). GM-CSF: a strong arteriogenic factor acting by amplification of monocyte function. Atherosclerosis 159:343-356.
7. Cai W, Vosschulte R, Afsah-Hedjri A, Koltai S, Kocsis E, Scholz D, Kostin S, Schaper W, Schaper J. (2000). Altered balance between extracellular proteolysis and antiproteolysis is associated with adaptive coronary arteriogenesis. J Mol Cell Cardiol 32:997-1011.
8. Cai WJ, Koltai S, Kocsis E, Scholz D, Schaper W, Schaper J. (2001). Connexin37, not Cx40 and Cx43, is induced in vascular smooth muscle cells during coronary arteriogenesis. J Mol Cell Cardiol 33:957-967.
9. Carmeliet P. (2000). Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389-395.
10. Carmeliet P, Collen D. Molecular analysis of blood vessel formation and disease. (1997). Am J Physiol 273:H2091-H2104.
11. Chae JK, Kim I, Lim ST, Chung MJ, Kim WH, Kim HG, Ko JK, Koh GY. (2000). Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization. Arterioscler Thromb Vasc Biol 20:2573-2578.
12. Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J, Risau W. (1996). The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 271:17629-17634.
13. De Marchis F, Ribatti D, Giampietri C, Lentini A, Faraone D, Scoccianti M, Capogrossi MC, Facchiano A. (2002). Platelet-derived growth factor inhibits basic fibroblast growth factor angiogenic properties in vitro and in vivo through its alpha receptor. Blood 99:2045-2053.
14. Demetri GD, Antman KH. (1992). Granulocyte-macrophage colony-stimulating factor (GM-CSF): preclinical and clinical investigations. Semin Oncol 19:362-385.
15. Denecker G, Vandenabcele P, Grooten J, Penning LC, Declercq W, Beyaert R, Buurman WA, Fiers W. (1997). Differential role of calcium in tumor necrosis factor-mediated apoptosis and secretion of granulocyte-macrophage colony-stimulating factor in a T cell hybridoma. Cytokine 9:631-638.
16. Dimmeler S, Dernbach E, Zeiher AM. (2000). Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett 477:258-262.
17. Donahue RE, Wang EA, Stone DK, Kamen R, Wong GG, Sehgal PK, Nathan DG, Clark SC. (1986). Stimulation of hematopoiesis in primates by continuous infusion of recombinant human GM-CSF. Nature 321:872-875.
18. Doukas J, Blease K, Craig D, Ma C, Chandler LA, Sosnowski BA, Pierce GF. (2002). Delivery of FGF genes to wound repair cells enhances arteriogenesis and myogenesis in skeletal muscle. Mol Ther 5:517-527.
19. Eischen A, Vincent F, Bergerat JP, Louis B, Faradji A, Bohbot A, Oberling F. (1991). Long term cultures of human monocytes in vitro. Impact of GM-CSF on survival and differentiation. J Immunol Methods 143: 209-221.
20. George D. (2001). Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin Oncol 28:27-33.
21. Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA Jr, Luster AD, Luscinskas FW, Rosenzweig A. (1999). MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398:718-723.
22. Hart MN, Fabry Z, Love-Homan L, Keiner J, Sadewasser KL, Moore SA. (1992). Brain microvascular smooth muscle and endothelial cells produce granulocyte macrophage colony-stimulating factor and support colony formation of granulocyte-macrophage-like cells. Am J Pathol 141:421-427.
23. Hawighorst T, Skobe M, Streit M, Hong YK, Velasco P, Brown LF, Riccardi L, Lange-Asschenfeldt B, Detmar M. (2002). Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol 160:1381-1392.
24. Heil M, Clauss M, Suzuki K, Buschmann IR, Willuweit A, Fischer S, Schaper W. (2000). Vascular endothelial growth factor (VEGF) stimulates monotype migration through endothelial monolayers via increased integrin expression. Eur J Cell Biol 79:850-857.
25. Heil M, Ziegelhoeffer T, Helisch A, Wagner S, Martin S, Kuziel W, Schaper W. (2002). Arteriogenesis (collateral artery growth) after femoral artery occlusion is reduced in mice lacking CC-chemokine-receptor-2. Circulation 106:1390.
26. Heil M, Ziegelhoeffer T, Pipp F, Kostin S, Martin S, Clauss M, Schaper W. (2002). Blood monocyte concentration is critical for enhancement of collateral artery growth. Am J Physiol Heart Circ Physiol 283:H2411-H2419.
27. Hoefer IE, van Royen N, Buschmann IR, Piek JJ, Schaper W. (2001). Time course of arteriogenesis following femoral artery occlusion in the rabbit. Cardiovasc Res 49:609-617.
28. Hoefer IE, van Royen N, Rectenwald JE, Bray EJ, Abouhamze Z, Moldawer LL, Voskuil M, Piek JJ, Buschmann IR, Ozaki CK. (2002). Direct evidence for tumor necrosis factor-alpha signaling in arteriogenesis. Circulation 105:1639-1641.
29. Hoekman K. (2001). SU6668, a multitargeted angiogenesis inhibitor. Cancer J 7:S134-S138.
30. Ishibashi T, Nakazato K, Shindo J, Yokoyama K, Maruyama Y. (1996). Effects of granulocyte-macrophage colony-stimulating factor on the levels of VLDL and LDL receptor mRNAs in vivo. J Atheroscler Thromb 2:76-80.
31. Ishida A, Murray J, Saito Y, Kanthou C, Benzakour O, Shibuya M, Wijelath ES. (2001). Expression of vascular endothelial growth factor receptors in smooth muscle cells. J Cell Physiol 188:359-368.
32. Ito WD, Arras M, Winkler B, Scholz D, Schaper J, Schaper W. (1997). Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ Res 80:829-837.
33. Jimenez B, Volpert OV. (2001). Mechanistic insights on the inhibition of tumor angiogenesis. J Mol Med 78:663-672.
34. Jones TC. (1993). The effects of rhGM-CSF on macrophage function. Eur J Cancer 29A:S10-S13.
35. Kanaki T, Bujo H, Mori S, Yanjuan Z, Takahashi K, Yokote K, Morisaki N, Saito Y. (2002). Functional analysis of aortic endothelial cells expressing mutant PDGF receptors with respect to expression of matrix metalloproteinase-3. Biochem Biophys Res Commun 294:231-237.
36. Klein B, Le Bousse-Kerdiles C, Smadja-Joffe F, Pragnell I, Ostertag W, Jasmin C. (1982). A study of added GM-CSF independent granulocyte and macrophage precursors in mouse spleen infected with myeloproliferative sarcoma virus (MPSV). Exp Hematol 10:373-382.
37. Koh GY, Kim I, Kwak HJ, Yun MJ, Leem JC. (2002). Biomedical significance of endothelial cell specific growth factor, angiopoietin. Exp Mol Med 34:1-11.
38. Lazarous DF, Unger EF, Epstein SE, Stine A, Arevalo JL, Chew EY, Quyyumi AA. (2000). Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. J Am Coll Cardiol 36: 1239-1244.
39. Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ, Annex BH. (2002). Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomized trial. Lancet 359:2053-2058.
40. Libby P, Sukhova G, Lee RT, Galis ZS. (1995). Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 25:S9-S12.
41. Mantzoros CS, Moschos SJ. (1998). Leptin: in search of role(s) in human physiology and pathophysiology. Clin Endocrinol (Oxf) 49:551-567.
42. Michiels C, Minet E, Michel G, Mottet D, Piret JP, Raes M. (2001). HIF-1 and AP-1 cooperate to increase gene expression in hypoxia: role of MAP kinases. IUBMB Life 52:49-53.
43. Nagel T, Resnick N, Atkinson WJ, Dewey CF Jr, Gimbrone MA Jr. (1994). Shear stress selectively upregulates intercellular adhesion molecule-1 expression in cultured human vascular endothelial cells. J Clin Invest 94:885-891.
44. Negishi M, Lu D, Zhang YQ, Sawada Y, Sasaki T, Kayo T, Ando J, Izumi T, Kurabayashi M, Kojima I, Masuda H, Takeuchi T. (2001). Upregulatory expression of furin and transforming growth factor-beta by fluid shear stress in vascular endothelial cells. Arterioscler Thromb Vasc Biol 21:785-790.
45. Neufeld G, Cohen T, Shraga N, Lange T, Kessler O, Herzog Y. (2002). The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc Med 12:13-19.
46. O'Connor DS, Schechner JS, Adida C, Mesri M, Rothermel AL, Li F, Nath AK, Pober JS, Altieri DC. (2000). Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 156:393-398.
47. Oda A, Taniguchi T, Yokoyama M. (2001). Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Med Sci 47:141-150.
48. Papetti M, Herman IM. (2002). Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 282:C947-C970.
49. Parhami F, Tintut Y, Ballard A, Fogelman AM, Demer LL. (2001). Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 88:954-960.
50. Pegram MD, Reese DM. (2002). Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin Oncol 29:29-37.
51. Pintucci G, Moscatelli D, Saponara F, Biernacki PR, Baumann FG, Bizekis C, Galloway AC, Basilico C, Mignatti P. (2002). Lack of ERK activation and cell migration in FGF-2-deficient endothelial cells. FASEB J 16:598-600.
52. Plenz G, Koenig C, Severs NJ, Robenek H. (1997). Smooth muscle cells express granulocyte-macrophage colony-stimulating factor in the undiseased and atherosclerotic human coronary artery. Arterioscler Thromb Vasc Biol 17:2489-2499.
53. Presta M, Rusnati M, Dell'Era P, Tanghetti E, Urbinati C, Giuliani R, Leali D. (2000). Examining new models for the study of autocrine and paracrine mechanisms of angiogenesis through FGF2-transfected endothelial and tumor cells. Adv Exp Med Biol 476:7-34.
54. Risau W. (1997). Mechanisms of angiogenesis. Nature 386:671-674.
55. Rosen LS. (2002). Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 9: 36-44.
56. Schaper W, Buschmann I. (1999). Arteriogenesis, the good and bad of it. Cardiovasc Res 43:835-837.
57. Schaper W, Buschmann I. (1999). Collateral circulation and diabetes. Circulation 99:2224-2226.
58. Schaper W, Ito WD. (1996). Molecular mechanisms of coronary collateral vessel growth. Circ Res 79:911-919.
59. Schoppmann SF, Birner P, Stockl J, Kalt R, Ullrich R, Caucig C, Kriehuber E, Nagy K, Alitalo K, Kerjaschki D. (2002). Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 161: 947-956.
60. Scotland RS, Morales-Ruiz M, Chen Y, Yu J, Rudic RD, Fulton D, Gratton JP, Sessa WC. (2002). Functional reconstitution of endothelial nitric oxide synthase reveals the importance of serine 1179 in endothelium-dependent vasomotion. Circ Res 90:904-910.
61. Seiler C, Pohl T, Wustmann K, Hutter D, Nicolet PA, Windecker S, Eberli FR, Meier B. (2001). Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation 104:2012-2017.
62. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA. Harvey VS, Dvorak HF. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985.
63. Shyy YJ, Hsieh HJ, Usami S, Chien S. (1994). Fluid shear stress induces a biphasic response of human monocyte chemotactic protein 1 gene expression in vascular endothelium. Proc Natl Acad Sci USA 91: 4678-4682.
64. Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Cardena G, Papapetropoulos A, Sessa WC, Madge LA, Schechner JS, Schwabb MB, Polverini PJ, Flores-Riveros JR. (1998). Biological action of leptin as an angiogenic factor. Science 281:1683-1686.
65. Spinetti G, Camarda G, Bernardini G, Romano Di Peppe S, Capogrossi MC, Napolitano M. (2001). The chemokine CXCL13 (BCA-1) inhibits FGF-2 effects on endothelial cells. Biochem Biophys Res Commun 289:19-24.
66. Valkovic T, Dobrila F, Melato M, Sasso F, Rizzardi C, Jonjic N. (2002). Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma. Virchows Arch 440:583-588.
67. van Royen N, Hoefer I, Buschmann I, Heil M, Kostin S, Deindl E, Vogel S, Korff T, Augustin H, Bode C, Piek JJ, Schaper W. (2002). Exogenous application of transforming growth factor beta 1 stimulates arteriogenesis in the peripheral circulation. FASEB J 16: 432-434.
68. Vikse BE, Bostad L, Aasarod K, Lysebo DE, Iversen BM. (2002). Prognostic factors in mesangioproliferative glomerulonephritis. Nephrol Dial Transplant 17: 1603-1613.
69. Visconti RP, Richardson CD, Sato TN. (2002). Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci USA 99: 8219-8224.
70. Vlodavsky I, Folkman J, Sullivan R, Fridman R, Ishai-Michaeli R, Sasse J, Klagsbrun M. (1987). Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci USA 84:2292-2296.
71. Wahl SM, Hunt DA, Wakefield LM, McCartney-Francis N, Wahl LM, Roberts AB, Sporn MB. (1987). Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 84:5788-5792.
72. Wetzel MA, Steele AD, Henderson EE, Rogers TJ. (2002). The effect of X4 and R5 HIV-1 on C, C-C, and C-X-C chemokines during the early stages of infection in human PBMCs. Virology 292:6-15.
73. Wiseman DM, Polverini PJ, Kamp DW, Leibovich SJ. (1988). Transforming growth factor-beta (TGF beta) is chemotactic for human monocytes and induces their expression of angiogenic activity. Biochem Biophys Res Commun 157:793-800.
74. Yanagisawa-Miwa A, Uchida Y, Nakamura F, Tomaru T, Kido H, Kamijo T, Sugimoto T, Kaji K, Utsuyama M, Kurashima C, Ito H. (1992). Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 257:1401-1403.
75. Zhang H, Issekutz AC. (2002). Down-modulation of monocyte transendothelial migration and endothelial adhesion molecule expression by fibroblast growth factor: reversal by the anti-angiogenic agent SU6668. Am J Pathol 160:2219-2230.
76. Zimmermann R, Arras M, Ullmann C, Strasser R, Sack S, Mollnau H, Schaper J, Schaper W. (1997). Time course of mitosis and collateral growth following coronary microembolization in the porcine heart. Cell Tissue Res 287:583-590.
77. Zubilewicz A, Hecquet C, Jeanny JC, Soubrane G, Courtois Y, Mascarelli F. (2001). Two distinct signaling pathways are involved in FGF2-stimulated proliferation of choriocapillary endothelial cells: a comparative study with VEGF. Oncogene 20:1403-1413.